Dalrada Technology Group reported a precarious liquidity position with a cash balance of $82.6K and a severe working capital deficit exceeding $22 million as of March 31, 2026, alongside a default notice from its lenders. The company operates through diversified subsidiaries spanning specialty pharmacy (Genefic), climate technology (Dalrada Climate Technology), precision manufacturing, and technology services. While pursuing commercialization of proprietary heat pump units and expanding construction projects internationally, Dalrada faces structural risks including continued net losses, legal battles over contractual disputes, and acute dependence on equity financing for operational funding. Monitoring upcoming contract milestones, resolution of litigation, and successful capital raises will be critical indicators of the company’s ability to sustain and grow its businesses.